Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) shares hit a new 52-week high on Tuesday . The company traded as high as $52.29 and last traded at $49.56, with a volume of 410133 shares. The stock had previously closed at $45.33.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised shares of Jyong Biotech to a "hold" rating in a research note on Monday, June 30th.
Check Out Our Latest Report on Jyong Biotech
Jyong Biotech Stock Up 7.3%
Jyong Biotech Company Profile
(
Get Free Report)
OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.
Further Reading
Before you consider Jyong Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.
While Jyong Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access